ArticleScientific reports2026
From prediction to action: developing a risk-stratified management tool for children with new-onset tic disorders.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Many children with provisional tic disorder (PTD) progress to chronic tics, but early risk stratification tools are lacking. In a prospective cohort of children with new-onset PTD, we developed a multivariable logistic regression model to predict 12-month progression to chronic tic disorders. The model was internally validated (bootstrap) and decision curve analysis was used to define risk thresholds. The final analytic cohort comprised 108 children. Three independent predictors of progression were identified: longer tic duration (adjusted odds ratio [aOR] = 1.18 per month, 95% CI: 1.01-1.38), higher parent tic questionnaire (PTQ) vocal score (aOR = 1.09 per point, 95% CI: 1.02-1.16), and presence of a comorbidity (aOR = 2.84, 95% CI: 1.01-8.02). A dual-threshold approach defined low- (< 30%), intermediate- (30-56%), and high-risk (≥ 56%) strata. The high-risk group had a 70.5% progression rate (vs. 27.3% in low-risk), a relative risk of 2.58, and a number needed to intervene of 2.3. The model was translated into a nomogram, online calculator, and risk-stratified management pathway. We provide a preliminary risk-stratified management tool that may support proactive and resource-efficient care for children with new-onset tics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.